New treatment options in spondyloarthropathies: Increasing evidence for significant efficacy of anti-tumor necrosis factor therapy

Current Opinion in Rheumatology

Volumn 13, Issue 4, 2001, Pages 245-249

  Braun, Jürgen ^a,b   De Keyser, Filip ^c   Brandt, Jan ^c   Mielants, Herman ^c   Sieper, Joachim ^c   Veys, Eric ^c  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC REACTION; ANKYLOSING SPONDYLITIS; AUTOIMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; GERMANY; HUMAN; IMMUNOPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; SPONDYLOARTHROPATHY; SYNOVIUM; TH1 CELL; TH2 CELL; THORACIC SPINE; TREATMENT OUTCOME; TUBERCULOSIS; URTICARIA;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CROHN DISEASE; HUMANS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034841503     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200107000-00001     Document Type: Review

References (46)

1. Prevalence of spondylarthropathies in HLA B27-positive and -negative blood donors
2. The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients
3. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database
4. Employment, work disability, and work days lost in patients with ankylosing spondylitis: A cross sectional study of Dutch patients
5. Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial
6. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug
7. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis
8. An open study of pamidronate in the treatment of refractory ankylosing spondylitis
9. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy
10. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis
11. Therapy of ankylosing spondylitis with Radiumchloride
12. The sacroiliac joint in the spondyloarthropathies
13. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis
14. T cells and macrophages predominate in early and active sacroiliitis as detected by magnetic resonance imaging in spondyloarthropathies
15. Immunohistological study of entheses in spondyloarthropathies: Comparison in rheumatoid arthritis and osteoarthritis
16. Nested PCR strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides
17. HLA B27-related arthritis and bowel inflammation: Sulfasalazine in HLA B27-related arthritis
18. Anti-tumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results and safety
19. Successful treatment of psoriatic arthritis with infliximab in an MRI-controlled study
20. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
21. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) -Fc fusion protein
22. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
23. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
24. A new approach to defining disease status in ankylosing spondylitis: The Bath AS Disease Activity Index
25. Anti-TNF-alpha: A new dimension in the pharmacotherapy of the spondyloarthropathies!?
26. Radiologic scoring methods in ankylosing spondylitis: Reliability and sensitivity to change over one year
27. The bath ankylosing spondylitis radiology index (BASRI): A new, validated approach to disease assessment
28. Radiological outcome in ankylosing spondylitis: Use of the Stoke Ankylosing Spondylitis Spine Score (SASSS)
29. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondyloarthropathy patients
30. Radiology and pathology of the spondyloarthropathies
31. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study
32. Crohn's disease associated with spondyloarthropathy: Effect of TNF-α blockade (infliximab) on the articular symptoms
33. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis
34. Evidence for a different cytokine secretion pattern of peripheral blood mononuclear cells of HLA B27+ patients with ankylosing spondylitis and HLA B27+ healthy controls compared to HLA B27-negative control
35. Differential Th1/Th2 cytokine patterns in chronic arthritis: Interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies
36. The elevated ratio of interferon gamma/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta
37. The impaired Th 1 cytokine production in spondyloarthropathy is restored by anti-TNF-α
38. Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy
39. Low T cell production of TNF-α and IFN-γ in ankylosing spondylitis: Its relation to HLA-B27 and influence of the TNF-308 gene polymorphism
40. Production, tissue distribution and function of IL-10 in psoriatic synovium
41. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis
42. IL-10 plasma levels correlate with disease activity in spondyloarthropathy
43. T cell cytokines in gut mucosa of patients with spondyloarthropathy reflect immune alterations in Crohn's disease
44. T cell counts and TNF-α secretion capacity in patients with ankylosing spondylitis after anti-TNF-α therapy
45. Treatment of spondyloarthropathies with antibodies against tumour necrosis factor-α: First clinical and laboratory experiences
46. Immunomodulatory effects of anti-TNF-α therapy on synovium in spondyloarthropathy